Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
INmune Bio Inc
INMBCurrent price
7.32 USD
+0.01 USD (+0.14%)
Last closed
7.30 USD
Company
www.inmunebio.com
ISIN
US45782T1051
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
167 849 792 USD
Yield for 12 month
-31.11 %
1Y
3Y
5Y
10Y
15Y
INMB
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
23.40 USDP/E ratio
–Dividend Yield
–Current Year
+14 000 USD
Last Year
+155 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+14 000 USD
Last Year
+155 000 USD
Current Quarter
–
Last Quarter
–
Key Figures INMB
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-55.19 %
PEG Ratio
–
Return On Equity TTM
-119.83 %
Wall Street Target Price
23.40 USD
Revenue TTM
14 000 USD
Book Value
1.44 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
14 000 USD
Earnings per share
-2.11 USD
Diluted Eps TTM
-2.11 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics INMB
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History INMB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation INMB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
10 522.28
Price Sales TTM
11 989.27
Enterprise Value EBITDA
-5.31
Price Book MRQ
5.23
Financials INMB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators INMB
For 52 weeks
4.32 USD
12.72 USD
50 Day MA
8.09 USD
Shares Short Prior Month
5 575 380
200 Day MA
6.76 USD
Short Ratio
23.33
Shares Short
6 060 191
Short Percent
32.85 %
BeatStart